Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Samsung Medical Center

Status and phase: Completed; Phase 2

Conditions: Stomach Neoplasms

Treatments: Drug: Gefitinib; Drug: Imatinib; Drug: Sunitinib

Study type: Interventional

Funder types: Other

Identifiers

NCT03170180

2016-12-058

Details and patient eligibility

About

1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study.
2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib).
3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs.
4. Patients will be evaluated every 6 weeks.

Enrollment: 66 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age>-20
• metastatic gastric cancer
• life expectancy >-3 months
• ascites and pleural effusion that can be drained
• ECOG 0-2
• Proper organ function
• Patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial

Exclusion criteria

• HBeAg, HCV, HIV (+)
• Active infection
• Uncontrolled systemic disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

66 participants in 3 patient groups

sunitinib

Experimental group

Treatment:

Drug: Sunitinib

gefitinib

Experimental group

Treatment:

Drug: Gefitinib

imatinib

Experimental group

Treatment:

Drug: Imatinib